DM1-SMe

CAT: 0804-HY-100128-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-100128-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin[1].
CAS Number
[138148-68-2]
UNSPSC
12352203
Hazard Statement
H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412
Target
ADC Payload; Microtubule/Tubulin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dm1-sme.html
Purity
99.08
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
Molecular Formula
C36H50ClN3O10S2
Molecular Weight
784.38
Precautions
H303, H312, H315, H317, H319, H335, H336, H351, H361, H372, H412
References & Citations
[1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60 (11) :1860-1867. |[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41 (1) :98-107.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Maytansinoids

Popular Products